Hopefully an inverse of what happened after UC.
Then, maybe a classic DNDN bear raid?
" Shortly before noon, someone named 'monthaphumchareon' posted the following announcement on Yahoo!'s DNDN message board:"
Then, hopefully, we will become a blue chip.
Yes, but I am not in NYC nor do I have access to high speed trading or any connection to those who do. My point is: Is Athersys ripe for the high speed traders? I think so.
Go to his site at Cleveland Clinic and see the SECOND video on his page.
Jeffrey Cohen, MD
The results will be in.
NASDAQ in NYC.
Either way the results turn out, speed will be the kingmaker.
There are approximately 25,000 HSCTs globally per year.1 Nearly 50% of these develop acute GVHD and a fraction of these will progress to severe GVHD which is steroid refractory. In patients that fail to respond to steroids, mortality can reach 85%. There are no approved therapies for acute GVHD. Standard of care is corticosteroids as a first line agent.
GlobalData estimates that the global GVHD therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018.
Osiris sold Prochymal for 100M + royalties.
The problem is, Prochymal costs $100,000 per dose.
Then you only have to ask yourself: MSC vs. MAPC?
You know the right side of history is most likely going to be stem cells for stroke treatment.
I believe he is growing MSCs.
He says they need 200-500 million cells.
Prochymal is an MSC, and each treatment for GvHD is about $100,000 USD.
As well all know, Multistem (MAPC) is can be amplified much easier than MSC at about 1/5 the cost for the same amount of cells.
MAPC, if it shows a signal of efficacy, is sitting pretty.
Method: Neuronal cells were subjected to stress, then followed by co-culture with MSCs.
Conclusion:Our studies have show that MSCs have anti-inflammatory properties and the capacity to rescue injured neurons. Cytotherapy 2014 Jun 10
Now, Dr. Zubair, a former Harvard Mecial School Clinical Fellow, is growing stem cells on the International Spece Station to amplify cells more rapidy, stabily, and uniformly for stroke.
The Auditorium is flanked on the ground floor by the Alsh and Boisdale Rooms both of which can accommodate 220 theatre style
Yes, someone posted about this, but its good to see it again.
For logjam, I always use fleet and eat more fiber.
But seriously, this is the kicker: Intracranial Atherosclerosis - the Most Common Cause of Stroke in the World - How Do We Manage? —David C. Hess, MD
You can't stent it and statins are marginally effective.
I do not think he will disclose the phase 2 Multistem for stroke trial results ahead of schedule (April 19th), but in his paper, he said he is looking for a signal of efficacy before doing a phase 2b or phase 3.
Read carefully though about the 19th. This will be the first presentation of the unblinded results...he could let something slip accidentally.
The presentation will take place at the European Stroke Organization Conference (ESOC) 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess' presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.
Trial enrollment was completed in December 2014 and this will be the first presentation of the unblinded results.
DNDN released phase 3b at a meeting.
It is tricky.
More so than you think.
Information about the oral abstracts may not be published or presented before the start of the session at AIDS 2014 in which the abstract is being presented.
Embargo Breaks for Presenters:
A committee will analyse potential cases of embargo break by presenters. These will be studied on a case by case basis and as an ultimate consequence it could lead to the abstract being withdrawn from the conference.
Authors may publish the fact that their abstract has been selected for inclusion in the AIDS 2014 programme, but may not publish the results of the study before the lifting of the embargo
Embargo Breaks for MEDIA REPORTERS:
As well as having access to the materials detailed above, THE MEDIA is also given prior access to the speakers' slides. However access is only granted to media onsite at the conference and the same embargo rules apply meaning the information in speakers slides cannot be referenced or published before the start of the presentation.
Breaking of the embargo policy by a reporter will lead to one or more of the following measures:
Immediate suspension of the reporter's media conference credentials
Immediate barring of the reporter from the meeting premises
Removal of the reporter's name from the IAS Media Distribution List for two years
No access to the next International AIDS Conference and IAS Conference
Any breaches in the embargo by media will be brought to the attention of the Media Embargo Committee. If you have questions, please contact the AIDS 2014 communications team